Logo image of AAPG

ASCENTAGE PHARMA GR-ADR (AAPG) Stock Fundamental Analysis

USA - NASDAQ:AAPG - ADR

39.78 USD
+0.2 (+0.51%)
Last: 10/2/2025, 12:19:55 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AAPG. AAPG was compared to 536 industry peers in the Biotechnology industry. Both the profitability and financial health of AAPG have multiple concerns. While showing a medium growth rate, AAPG is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AAPG has reported negative net income.
AAPG had a negative operating cash flow in the past year.
AAPG had negative earnings in each of the past 5 years.
AAPG had a negative operating cash flow in each of the past 5 years.
AAPG Yearly Net Income VS EBIT VS OCF VS FCFAAPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500M -1B

1.2 Ratios

Looking at the Return On Assets, with a value of -15.49%, AAPG belongs to the top of the industry, outperforming 81.16% of the companies in the same industry.
AAPG has a Return On Equity of -153.46%. This is in the lower half of the industry: AAPG underperforms 62.87% of its industry peers.
Industry RankSector Rank
ROA -15.49%
ROE -153.46%
ROIC N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
AAPG Yearly ROA, ROE, ROICAAPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

AAPG's Gross Margin of 97.03% is amongst the best of the industry. AAPG outperforms 96.46% of its industry peers.
In the last couple of years the Gross Margin of AAPG has grown nicely.
The Profit Margin and Operating Margin are not available for AAPG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
AAPG Yearly Profit, Operating, Gross MarginsAAPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

AAPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
AAPG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AAPG has been increased compared to 5 years ago.
AAPG has a better debt/assets ratio than last year.
AAPG Yearly Shares OutstandingAAPG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AAPG Yearly Total Debt VS Total AssetsAAPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

AAPG has an Altman-Z score of 3.43. This indicates that AAPG is financially healthy and has little risk of bankruptcy at the moment.
AAPG has a better Altman-Z score (3.43) than 71.64% of its industry peers.
A Debt/Equity ratio of 4.46 is on the high side and indicates that AAPG has dependencies on debt financing.
With a Debt to Equity ratio value of 4.46, AAPG is not doing good in the industry: 81.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 4.46
Debt/FCF N/A
Altman-Z 3.43
ROIC/WACCN/A
WACC8.34%
AAPG Yearly LT Debt VS Equity VS FCFAAPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 1.26 indicates that AAPG should not have too much problems paying its short term obligations.
AAPG's Current ratio of 1.26 is on the low side compared to the rest of the industry. AAPG is outperformed by 84.33% of its industry peers.
A Quick Ratio of 1.26 indicates that AAPG should not have too much problems paying its short term obligations.
AAPG has a worse Quick ratio (1.26) than 83.77% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.26
AAPG Yearly Current Assets VS Current LiabilitesAAPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

AAPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -184.96%.
The Revenue for AAPG has decreased by -56.75% in the past year. This is quite bad
The Revenue has been growing by 132.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-184.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-409.56%
Revenue 1Y (TTM)-56.75%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%-71.63%

3.2 Future

Based on estimates for the next years, AAPG will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.65% on average per year.
Based on estimates for the next years, AAPG will show a very strong growth in Revenue. The Revenue will grow by 23.37% on average per year.
EPS Next Y-186.08%
EPS Next 2Y103.96%
EPS Next 3Y9.65%
EPS Next 5YN/A
Revenue Next Year-42.1%
Revenue Next 2Y64.73%
Revenue Next 3Y21.33%
Revenue Next 5Y23.37%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AAPG Yearly Revenue VS EstimatesAAPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AAPG Yearly EPS VS EstimatesAAPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AAPG. In the last year negative earnings were reported.
AAPG is valuated quite expensively with a Price/Forward Earnings ratio of 32.50.
Based on the Price/Forward Earnings ratio, AAPG is valued cheaply inside the industry as 90.11% of the companies are valued more expensively.
AAPG is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.21, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 32.5
AAPG Price Earnings VS Forward Price EarningsAAPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AAPG Per share dataAAPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.96%
EPS Next 3Y9.65%

More info and screens

0

5. Dividend

5.1 Amount

AAPG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASCENTAGE PHARMA GR-ADR

NASDAQ:AAPG (10/2/2025, 12:19:55 PM)

39.78

+0.2 (+0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/bmo
Earnings (Next)N/A N/A
Inst Owners9.3%
Inst Owner Change-65.52%
Ins Owners12.74%
Ins Owner ChangeN/A
Market Cap3.70B
Analysts86.15
Price Target43.88 (10.31%)
Short Float %0.02%
Short Ratio1.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.21%
PT rev (3m)25.63%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-16.72%
EPS NY rev (3m)-3.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)5.66%
Revenue NY rev (3m)12.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 32.5
P/S 26.85
P/FCF N/A
P/OCF N/A
P/B 99.66
P/tB 161.03
EV/EBITDA N/A
EPS(TTM)-1.83
EYN/A
EPS(NY)1.22
Fwd EY3.08%
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS1.48
BVpS0.4
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.49%
ROE -153.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.03%
FCFM N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 4.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.07%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.26
Quick Ratio 1.26
Altman-Z 3.43
F-Score5
WACC8.34%
ROIC/WACCN/A
Cap/Depr(3y)161.69%
Cap/Depr(5y)588.72%
Cap/Sales(3y)47.03%
Cap/Sales(5y)745.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-409.56%
EPS Next Y-186.08%
EPS Next 2Y103.96%
EPS Next 3Y9.65%
EPS Next 5YN/A
Revenue 1Y (TTM)-56.75%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%-71.63%
Revenue Next Year-42.1%
Revenue Next 2Y64.73%
Revenue Next 3Y21.33%
Revenue Next 5Y23.37%
EBIT growth 1Y57.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-261.73%
EBIT Next 3Y-20.86%
EBIT Next 5YN/A
FCF growth 1Y82.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.66%
OCF growth 3YN/A
OCF growth 5YN/A